Early access
Sign in
Not yet taking people in United StatesNo phase

Genetic markers that may show how Barrett's esophagus responds to endoscopic treatment

Studies tissue samples to find genetic markers in people with Barrett's esophagus having endoscopic treatment.

Key facts

Who runs it
UNC Lineberger Comprehensive Cancer Center
Where
Chapel Hill, United StatesSee the site
Trial code
Registry title
Lucid BE Biomarkers Study
Status
Not yet recruiting
People taking part
40 people, planned
Starts
Dec 2026
Expected to end
Feb 2034
Type of study
Observational
Treatments tested
  • Tissue
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Barrett's esophagus with abnormal cells (dysplasia) or early esophageal cancer (T1a). They must be scheduled for radiofrequency ablation or cryoablation, two treatments done through a scope that destroy the abnormal lining. Tissue samples and data will be collected.

Age
18 years or older
Sex
All sexes
Disease stage
Barrett's esophagus with low grade dysplasia (LGD) or high grade dysplasia (HGD), or T1a esophageal adenocarcinoma (EAC).
Earlier treatment
Must not have started any session of endoscopic eradication therapy (EET) before consent.

Main reasons for not taking part

  • Barrett's esophagus without dysplasia, or where dysplasia is uncertain (indefinite)
  • Treatment plan that may include endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)
  • Other esophagus disease, such as Eosinophilic Esophagitis (EoE), that could disturb the test results
  • Current use of blood thinners such as coumadin, warfarin, clopidogrel, heparin or low molecular weight heparin, unless stopped as required
  • Known bleeding disorder, or biopsies during a scope exam not safe

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information
  • Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee
  • Age ≥ 18 years at the time of consent
  • Scheduled to undergo radiofrequency ablation (RFA) or cryoablation of either dysplastic Barrett's Esophagus (BE with low grade dysplasia (LGD) or high grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC)
  • Have not yet initiated first session of endoscopic eradication therapy (EET1) at the time of consent

Who cannot take part

  • Patients in whom the initial treatment plan includes potential for endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)
  • Patients with concomitant esophageal pathology such as Eosinophilic Esophagitis (EoE) which in the opinion of the investigator may produce confounding biomarker signals
  • Current use of blood thinners such as coumadin, warfarin, clopidogrel, heparin and/or low molecular weight heparin (requires discontinuation of medication 5 days prior to and 6 days after esophagogastroduodenoscopy [EGD] and/or ensuring blood thinners have been stopped within an appropriate time frame for that specific agent and in accordance with standard clinical practice)
  • Known bleeding disorder
  • Younger than age 18 years
  • Patients with non-dysplastic BE (NDBE) or are indefinite for dysplasia (IND)
  • Patients who have already initiated 1 or more rounds of EET before time of consent
  • Patients in which even a limited number of biopsies during Esophagogastroduodenoscopy (EGD) would be contraindicated
  • Patients currently enrolled in any clinical research study involving products or interventions that, in the judgment of the investigator, could impact or interfere with this study

Where in United States

  • UNC- Chapel HillChapel Hill, United StatesContact: Shilpa KaranjitNot yet recruiting

About the trial

What the trial wants to find out

The goal of this study is to learn more about genetic factors that may predict if patients with Barrett's Esophagus (BE) will respond to endoscopic treatment. Patients undergoing endoscopic eradication therapy (EET) for their BE may be eligible. After eligibility is confirmed and informed consent is complete, samples and data will be collected for use in this study.

The group in the trial

  • Endoscopic Eradication Therapy (EET)

    Patients undergoing radiofrequency ablation (RFA) or cryoablation of either dysplastic Barrett's Esophagus (BE with low grade dysplasia (LGD) or high grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC).

    Treatment: Tissue

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Exploratory Analysis of Biomarkers That May Signal Changes in Disease Status During Endoscopic Eradication Therapy (EET) for Barrett's Metaplasia and Neoplasia
Plain-language title
Genetic markers that may show how Barrett's esophagus responds to endoscopic treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
21 October 2026